AMD Central

Bispecific agents appear promising in broadening the treatment landscape in wet age-related macular degeneration and diabetic macular edema, but much remains to be learned about this emerging class of agents.

The potential of artificial intelligence for the diagnosis and management of age-related macular degeneration is vast.

Stem cell therapy still has many hurdles to clear before becoming a viable therapeutic option for age-related macular degeneration, but it may have the potential to transform treatment in the future.

Novel therapies for patients with age-related macular degeneration as well as the impact of the COVID-19 pandemic on treatment for this population were popular topics at ophthalmology meetings in 2021.

Gene therapy could have the potential to revolutionize the treatment of many conditions, including age-related macular degeneration.

Age-related macular degeneration is one of the leading causes of vision loss in the elderly population. Although new treatments have been beneficial in reducing vision loss and slowing the disease, they often come with a difficult burden.

Due to the COVID-19 pandemic, 2020 was marked by innovation and rapid advances in medicine, and the field of ophthalmology was no exception. With the unveiling of important data on age-related macular degeneration at the year’s major conferences, physicians may soon see these changes reflected in clinical practice.